Z. Ying

Publications109
h-index14
Citations5,893
Highly Influential Citations1,305
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • Jun Zhu
  • 284 Publications • 3,369 Citations
  • G. Salles
  • 1,059 Publications • 46,962 Citations
  • R. Gascoyne
  • 944 Publications • 91,513 Citations
  • C. June
  • 917 Publications • 95,889 Citations
  • Publications
  • Influence
Inductive Representation Learning on Large Graphs
TLDR
GraphSAGE is presented, a general, inductive framework that leverages node feature information (e.g., text attributes) to efficiently generate node embeddings for previously unseen data and outperforms strong baselines on three inductive node-classification benchmarks.
A safe and potent anti-CD19 CAR T cell therapy
TLDR
Therapy with the new CD19-BBz(86) CAR T cells produces a potent and durable antilymphoma response without causing neurotoxicity or severe CRS, representing a safe and potent anti-CD19 CAR T cell therapy.
A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type
TLDR
CHOP-L chemotherapy in combination with radiotherapy is a safe and highly effective treatment for newly diagnosed ENKTL and the major adverse events were myelosuppression, liver dysfunction, and digestive tract toxicities.
Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin
TLDR
It is concluded that 13.8% of DLBCL cases are HBV-associated inHBV-endemic China and show unique clinical features and poor outcomes and strongly suggests that HBv-associatedDLBCL might arise from HBV antigen-selected B cells.
Extranodal natural killer/T cell lymphoma: we should and we can do more.
TLDR
Risk-stratification is needed for ENKL because the prognostic factors include IPI, KIPI, plasma EBV-DNA, and interim-PET/CT are not validated in the era of L-asparaginase.
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
  • Z. Ying, T. He, Jun Zhu
  • Medicine, Biology
    Molecular therapy oncolytics
  • 28 August 2019
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
  • Yizi He, Jiao Li, Jun Zhu
  • Biology, Medicine
    Journal of experimental & clinical cancer…
  • 18 February 2019
TLDR
Combination of enzastaurin and ibrutinib had synergistic anti-tumor effects in DLBCL, independent of molecular subtype, which provided a sound foundation for an attractive therapeutic treatment, and the simultaneous suppression of BTK and PKCβ might be a new treatment strategy forDLBCL.
Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome
TLDR
Patients with extranodal NK/T cell lymphoma was frequently complicated with HPS, and survival was discouraging in this circumstance, and intensive chemotherapy regimens including l-asparaginase or pegaspargase and allogeneic stem cell transplantation should be investigated.
Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell…
TLDR
Early interim 18F-FDG PET/CT effectively predicts the outcome in patients with DLBCL using SUVmax-liver-based interpretation, and was independent predictor for PFS and OS.
Can the SUVmax-liver-based interpretation improve prognostic accuracy of interim and posttreatment 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma?
TLDR
The SUVmax-liver-based interpretation were superior to 5-point scale and %ΔSUVmax criteria in analyzing the PET-4 and PET-end for the prognosis of DLBCL patients.
...
1
2
3
4
5
...